Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) saw some unusual options trading activity on Tuesday. Traders bought 43,297 call options on the company. This represents an increase of 601% compared to the typical volume of 6,178 call options.
Tempus AI Price Performance
Shares of TEM traded up $12.49 during trading hours on Tuesday, hitting $47.64. The company had a trading volume of 33,103,118 shares, compared to its average volume of 6,320,173. The firm has a fifty day moving average price of $44.77 and a 200-day moving average price of $47.39. Tempus AI has a 52-week low of $22.89 and a 52-week high of $79.49. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.
Analyst Ratings Changes
A number of brokerages have recently weighed in on TEM. Needham & Company LLC reaffirmed a "buy" rating and set a $56.00 target price on shares of Tempus AI in a research note on Tuesday, January 14th. Piper Sandler reaffirmed a "neutral" rating and set a $70.00 price objective (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Bank of America increased their target price on Tempus AI from $52.00 to $54.00 and gave the stock a "neutral" rating in a research report on Friday, December 13th. Loop Capital dropped their price target on Tempus AI from $57.00 to $52.00 and set a "buy" rating on the stock in a research report on Tuesday, January 14th. Finally, Wolfe Research started coverage on Tempus AI in a research note on Friday, December 13th. They issued an "outperform" rating and a $60.00 price target on the stock. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, Tempus AI currently has an average rating of "Moderate Buy" and an average target price of $56.36.
Check Out Our Latest Analysis on TEM
Insider Activity at Tempus AI
In other Tempus AI news, COO Ryan Fukushima sold 120,000 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $42.51, for a total value of $5,101,200.00. Following the completion of the sale, the chief operating officer now owns 1,007,207 shares in the company, valued at approximately $42,816,369.57. This trade represents a 10.65 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Bradley A. Keywell sold 395,800 shares of the business's stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total value of $16,999,610.00. Following the transaction, the insider now directly owns 16,164,449 shares in the company, valued at $694,263,084.55. This trade represents a 2.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,300,761 shares of company stock worth $51,271,197 in the last three months.
Institutional Trading of Tempus AI
Institutional investors and hedge funds have recently bought and sold shares of the company. NEA Management Company LLC bought a new position in shares of Tempus AI during the second quarter valued at $160,048,000. Novo Holdings A S bought a new position in Tempus AI during the 2nd quarter valued at about $142,605,000. ARK Investment Management LLC boosted its holdings in shares of Tempus AI by 355.0% during the 3rd quarter. ARK Investment Management LLC now owns 2,378,157 shares of the company's stock valued at $134,604,000 after acquiring an additional 1,855,459 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Tempus AI by 1,591.2% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company's stock worth $68,922,000 after acquiring an additional 1,145,698 shares during the period. Finally, Perceptive Advisors LLC purchased a new position in shares of Tempus AI during the second quarter valued at approximately $9,625,000. 24.22% of the stock is currently owned by institutional investors.
About Tempus AI
(
Get Free Report)
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Read More
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
